Strategic Partnerships Amphivena is a private clinical-stage immuno-oncology company with a novel T cell engager platform (Amphivena ReSTORE) targeting myeloid-derived suppressor cells. This presents partnership opportunities with larger biotechs, pharma players, and CROs focusing on immune-oncology, solid tumors, or combinations to enhance immune activation and manage CRS.

Financial Backing With a funding level of $136 million and a recent Series C, Amphivena is positioned for expansion of clinical development. This indicates potential appetite for strategic collaboration, licensing, or co-development deals to accelerate trials or expand into additional indications, particularly solid tumors.

Clinical Momentum Historical milestones include the Phase 1 initiation in MDS and leadership hires such as a new CEO in 2019 and a Chief Scientific Officer appointment. This demonstrates ongoing clinical activity and leadership capability, making them a candidate for early-to-mid stage collaboration on trial design, biomarker development, or platform validation.

Targeted Need The focus on relieving cancer-induced immune suppression by depleting MDSCs and controlling cytokine release syndrome positions Amphivena to partner with suppliers or vendors offering CRS management, immune profiling, hematology biomarkers, or AKI/CRS monitoring technologies that complement their T cell engager platform.

Market Positioning Operating with a lean team and a niche platform in immuno-oncology, Amphivena presents a compelling co-development or licensing target for mid-size pharma and investors seeking specialized oncology assets with scalable manufacturing and regulatory pathways to treat myeloid-derived malignancies and potential solid tumor indications.